A step further in a vaccine for Escherichia coli.

[1]  A. Goldman,et al.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets , 2019, Medical Microbiology and Immunology.

[2]  R. Frenck,et al.  Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. , 2019, The Lancet. Infectious diseases.

[3]  I. Henderson,et al.  A Novel Method of Serum Resistance by Escherichia coli That Causes Urosepsis , 2018, mBio.

[4]  J. Poolman,et al.  Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine , 2017, Clinical and Vaccine Immunology.

[5]  E. Bernasconi,et al.  Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. , 2017, The Lancet. Infectious diseases.

[6]  J. Poolman,et al.  Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field , 2015, The Journal of infectious diseases.

[7]  Z. Tandoğdu,et al.  Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013 , 2015, World Journal of Urology.

[8]  R. Sorek,et al.  Fur Is the Master Regulator of the Extraintestinal Pathogenic Escherichia coli Response to Serum , 2014, mBio.

[9]  P. Reeves.  Role of O-antigen variation in the immune response. , 1995, Trends in microbiology.

[10]  A. Cross,et al.  Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. , 1994, The Journal of infectious diseases.

[11]  A. Shelokov,et al.  Antibody-coated bacteria in the urine and the site of urinary-tract infection. , 1974, The New England journal of medicine.